Paraquat Lawsuit Settlements: What Victims May Receive in 2026

Current MDL 3004 Status

The paraquat litigation is currently consolidated in Multidistrict Litigation MDL 3004, formally captioned In re: Paraquat Products Liability Litigation, pending before Judge Nancy Rosenstengel in the United States District Court for the Southern District of Illinois. MDL consolidation allows thousands of individually filed lawsuits to be coordinated for pretrial proceedings — including discovery, expert witness challenges, and case management — while preserving each plaintiff's right to individual resolution.

The MDL has been actively proceeding through critical pretrial stages. A pivotal phase involved Daubert hearings — judicial proceedings where the court evaluates whether expert witnesses' scientific opinions are sufficiently reliable and relevant to be presented to a jury. The outcome of Daubert challenges in paraquat litigation is particularly consequential because the core scientific question — whether paraquat causes Parkinson's disease — depends heavily on expert epidemiological and toxicological testimony.

The primary defendants are Syngenta AG and its affiliates (as manufacturers and marketers of Gramoxone) and Chevron Phillips Chemical Company (as a prior registrant and marketer of paraquat products). Both defendants have vigorously contested causation, arguing that the scientific evidence linking paraquat to Parkinson's disease does not meet the legal standards for admissible expert testimony. The court's rulings on these challenges will significantly shape the litigation's trajectory.

Settlement Expectations in 2026

As of 2026, no global settlement has been publicly announced in the paraquat MDL, and the litigation continues to be actively litigated. However, the structure and trajectory of the MDL provide important context for understanding when and how a resolution might occur.

In most major pharmaceutical and pesticide MDLs, a global settlement becomes possible only after several key milestones: (1) the court has resolved the major Daubert challenges to expert witnesses, establishing which scientific opinions will be admissible at trial; (2) bellwether trials have been conducted, giving both sides a realistic assessment of jury verdicts; and (3) the parties have exchanged substantial information through discovery that allows realistic valuation of the claims.

Settlement amounts in comparable pesticide and environmental toxic tort litigation have varied enormously based on the strength of the scientific evidence, the number of claimants, and the defendants' financial capacity. The Roundup weed killer litigation — which involves similar issues of agricultural herbicide exposure and cancer risk — resulted in Bayer agreeing to pay approximately $10.9 billion to resolve approximately 100,000 claims, reflecting a broad range of individual settlement values depending on severity of illness and strength of exposure evidence.

While specific paraquat settlement amounts are not publicly available as of this writing, attorneys working on these cases have consistently advised claimants that the value of individual claims will depend heavily on the factors described in the next section. The severity of the Parkinson's disease diagnosis and the strength of the exposure evidence are the primary drivers of individual claim value.

Factors That Affect Compensation

In any personal injury mass tort litigation, individual case value is determined by a combination of factors that reflect both the severity of harm suffered and the strength of the legal evidence. Paraquat claimants with stronger exposure history and more severe Parkinson's disease presentations are generally expected to command higher compensation.

Medical Severity Factors

• Stage and severity of Parkinson's disease at the time of settlement or trial (more advanced disease typically yields higher compensation)
• Age at Parkinson's disease onset (younger onset — especially before age 60 — is associated with higher damages due to longer disease duration and greater loss of earning capacity)
• Whether the claimant requires assisted living, home health care, or other expensive medical interventions
• Documented medical expenses and anticipated future medical costs
• Impact on the claimant's ability to work and earn income (lost wages and future earning capacity)
• Non-economic damages: pain and suffering, loss of enjoyment of life, loss of consortium for spouses and family members

Exposure Strength Factors

• Duration of paraquat exposure (years of use)
• Frequency and intensity of exposure (daily applicator vs. occasional bystander)
• Documentation quality (well-documented exposure with records vs. reconstructed history)
• Proximity to application site for residential exposure claimants
• Whether co-exposure to synergistic pesticides like maneb is documented

Defendants' attorneys will scrutinize both the medical evidence and the exposure history in an attempt to minimize claim value. Alternative causes of Parkinson's disease — such as family history, advanced age, or exposure to other chemicals — may be raised as potential confounders. This is why thorough documentation of both the exposure history and the medical progression of Parkinson's disease is so important from the earliest stages of the claim.

Types of Damages Available

Paraquat lawsuit plaintiffs may be entitled to several categories of compensation, depending on their state's law and the specific facts of their case.

Compensatory Damages

• Medical expenses: past and future costs of Parkinson's disease treatment, including neurologist visits, medications (levodopa, dopamine agonists), physical therapy, occupational therapy, and surgical interventions like deep brain stimulation
• Lost wages: income lost due to the inability to work as Parkinson's disease progresses
• Future lost earning capacity: projected income loss over the remainder of a claimant's working life
• Home care and assisted living costs: expenses for in-home assistance, adult day programs, or residential care facilities
• Pain and suffering: compensation for physical pain, emotional distress, anxiety, and depression associated with a Parkinson's disease diagnosis
• Loss of consortium: damages for the impact of Parkinson's disease on the claimant's marriage and family relationships

Punitive Damages

In some jurisdictions and under certain factual circumstances, plaintiffs may also seek punitive damages — additional compensation designed to punish defendants for particularly egregious conduct and deter future wrongdoing. Punitive damages are typically only available where there is evidence that the defendant acted with actual malice, reckless disregard for safety, or deliberate concealment of known hazards. Internal corporate documents produced in discovery may be central to establishing the factual basis for punitive damage claims.

Wrongful Death Claims

If a paraquat-exposed individual who had Parkinson's disease has passed away, surviving family members — typically a spouse or adult children — may be able to file a wrongful death claim seeking compensation for the loss of their loved one, including medical expenses incurred prior to death, funeral and burial expenses, and loss of companionship.

Bellwether Trials and Their Importance

A key feature of mass tort MDL litigation is the use of bellwether trials — individual cases selected to go to trial before the broader MDL resolves. These cases are chosen to be representative of the range of claims in the litigation, and their outcomes provide both sides with critical information for evaluating settlement.

A plaintiff's verdict in bellwether trials — particularly a large one — typically accelerates settlement negotiations by demonstrating that juries are willing to award substantial damages against the defendants. A defense verdict, by contrast, can embolden defendants to push harder on contested scientific issues and hold out for more favorable settlement terms. In large pharmaceutical and chemical MDLs, the outcomes of just a few bellwether trials can determine whether the overall litigation settles for billions of dollars or continues to trial for years.

In the paraquat MDL, the scheduling and conduct of bellwether trials will be closely watched by attorneys on both sides of the litigation, by the plaintiff and defendant companies, and by agricultural and public health advocates who have been pressing for stronger paraquat regulation. The first bellwether trial verdicts are expected to be a watershed moment in the litigation's history.

What Is the Expected Timeline?

Mass tort MDL litigation is notoriously difficult to predict in terms of timeline. The paraquat MDL has been proceeding through discovery and pretrial motions practice since its formation, and the resolution of key Daubert challenges to expert witnesses will be a critical milestone.

Based on the typical arc of large pharmaceutical and chemical MDLs:

• Near-term: Resolution of Daubert challenges to expert witnesses — determining which scientific opinions can be presented to juries
• Mid-term: Bellwether trial selection and scheduling; first trials expected to provide crucial data on jury receptiveness to causation and damages evidence
• Longer-term: Global settlement negotiations typically intensify after bellwether trials; individual settlement offers may begin rolling out to claimants as the MDL approaches resolution
• Ongoing: New case filings continue to be added to the MDL as newly diagnosed Parkinson's patients with paraquat exposure histories become aware of the litigation

Given the complexity of the scientific issues, the resources of the defendants (Syngenta is a major multinational agrochemical company), and the large number of claimants, the paraquat MDL may take several additional years to fully resolve. However, individual claimants should not wait to file their claims — statutes of limitations mean that delay can permanently forfeit your right to compensation.

Frequently Asked Questions